IVERIC bio, Inc. (NASDAQ:ISEE) was founded in 2007, formerly known as Ophthotech Corporation (爱眼科技, formerly NASDAQ:OPHT), headquartered in New York, USA, changed to its current name in April 2019, with 44 full-time employees , Is a biopharmaceutical company focused on developing innovative therapies to treat ophthalmic diseases, with a focus on age-related and isolated retinal diseases.
IVERIC bio, Inc. (ISEE):
IVERIC bio is developing complement factor C5 inhibitor Zimura ® , which is in phase IIb clinical trials for the treatment of geographic atrophy (GA), which is the advanced form of dry macular degeneration (AMD), which is characterized by retinal cell death , Tissue degeneration in the central part of the retina called the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan hereditary retinopathy (IRD).
IVERIC bio is also developing high-temperature demand A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of dry AMD and other age-related retinal diseases (such as wet AMD and idiopathic polypoid choroid vasculitis) ) GA.
- Fovista (Fovista ® anti-PDGF therapy) -used in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (AMD). It is currently in the phase III clinical trial phase, and results are expected to be available by the end of 2016;
- Zimura (Zimura ® ) —— Complement factor C5 inhibitor, used for the treatment of dry AMD and specific forms of wet AMD. The IIa clinical trial has been completed and the II/III clinical trial is about to be carried out.
IVERIC bio and Nei Keta treatment (Nektar Therapeutics) signed a cooperation agreement.
IVERIC bio has signed a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retina Pigmentation (RHO-adRP); BEST disease and other skin diseases.
IVERIC bio also signed a research agreement with the University of Massachusetts Medical School to use micro-gene therapy to develop AAV gene therapy product candidates for Leber congenital Amorol disease type 10 and STGD1; and evaluate various AAVs The potential application of gene delivery methods in the eyes.